Education
About Us
Working with TipRanks
Follow Us
Celcuity Inc. (CELC)
:CELC
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.88Last Year’s EPS
-0.62Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -1.57%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments in clinical trials and potential market opportunities, contrasted by increased financial losses and operational cash burn. The anticipation for upcoming data readouts is high, but there are concerns about financial sustainability.Company Guidance
During the Celcuity First Quarter 2025 Financial Results Webcast Conference Call, the company provided guidance on several key metrics. Celcuity expects to report topline data from the PIK3CA wild-type cohort of their Phase 3 VIKTORIA-1 trial by Q3 2025, with data from the PIK3CA mutated cohort anticipated in Q4 2025. The company also plans to release preliminary data from a Phase 1b prostate cancer trial by the end of Q2 2025. They foresee significant revenue potential if their programs receive regulatory approval, estimating a $2 billion peak revenue potential for their second-line indication with gedatolisib if they achieve 40% market penetration. Financially, Celcuity reported a Q1 2025 net loss of $37 million, noting a 49% increase in R&D expenses compared to Q1 2024, and closed the quarter with $205.7 million in cash and equivalents, projecting funding through 2026.Upcoming Clinical Data Readouts
Celcuity expects to report topline data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial in Q3 2025 and from the PIK3CA mutated patient cohort in Q4 2025, indicating significant progress in their clinical trials.
Potential Revenue from Gedatolisib
If gedatolisib receives FDA approval for both PIK3CA wild-type and mutant populations, the estimated peak revenue potential for the second-line indication could exceed $2 billion with 40% market penetration.
Advancements in VIKTORIA-2 Trial
Significant progress in activating trial sites for the Phase 3 first-line VIKTORIA-2 trial, with nearly 200 sites qualified across multiple regions.
Endometrial Cancer Collaboration
Celcuity announced a collaboration with Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancer.
---
CELC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CELC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $10.86 | $10.52 | -3.13% |
Mar 31, 2025 | $10.11 | $9.29 | -8.11% |
Nov 14, 2024 | $14.11 | $12.66 | -10.28% |
Aug 14, 2024 | $16.33 | $15.77 | -3.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Celcuity Inc. (CELC) report earnings?
Celcuity Inc. (CELC) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Celcuity Inc. (CELC) earnings time?
Celcuity Inc. (CELC) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CELC EPS forecast?
CELC EPS forecast for the fiscal quarter 2025 (Q2) is -0.88.
---